Recombinant Mouse Anti-TF(Galβ1-3GalNAcα) Antibody (JAA-F11) (CAT#: PABW-164)

Figure 1 Representative JAA-F11 antibody staining of matched human breast cancer with metastatic lymph nodes.

Two representative cases from two patients with invasive ductal breast carcinoma with pathologic diagnosis as documented by US Biomax are shown. Case 1 (A-D) and case 2 (E-H) are shown with JAA-F11 staining specifically (left) compared to matched isotype mIgG3 control (right). Each case was compared for the original breast carcinoma to the metastatic lymph of each patient (A, B to C, D and E, F to G, H). Magnification: 40×.

Karacosta, L. G., Fisk, J. C., Jessee, J., Tati, S., Turner, B., Ghazal, D., ... & Koury, S. (2018). Preclinical Analysis of JAA-F11, a Specific Anti–Thomsen-Friedenreich Antibody via Immunohistochemistry and In Vivo Imaging. Translational oncology, 11(2), 450-466.

Figure 2 Flow cytometric analysis of TF-Ag Expression on Human Cancer cells.

C. binding of hJAA-F11 constructs H2aL2a and H3L3 to HTB-171 detected with Goat-anti-human IgG-biotin/Streptavidin-PE.

Tati, S., Fisk, J. C., Abdullah, J., Karacosta, L., Chrisikos, T., Philbin, P., ... & Quataert, S. (2017). Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and InVitro Efficacy Analysis. Neoplasia, 19(9), 716-733.

Figure 3 ADCC activity versus TF-Ag positive breast and lung cancer cell lines by 7a) H2aL2a and chimeric antibodies at 200 μg/ml, and 7b) H3L3 and H2aL2a Ab at 50 μg/ml.

C. 200 μg/ml concentrations of either H2aL2a were added to BT549 cells. The mouse JAA-F11, effectively a negative control antibody did not show appreciable ADCC even at 200 μg/ml with the BT549 cells. In the HTB-171 and MDA-MB-231 cell lines with H2aL2a, there was no appreciable ADCC activity above background and was not graphed.

Tati, S., Fisk, J. C., Abdullah, J., Karacosta, L., Chrisikos, T., Philbin, P., ... & Quataert, S. (2017). Humanization of JAA-F11, a Highly Specific Anti-Thomsen-Friedenreich Pancarcinoma Antibody and InVitro Efficacy Analysis. Neoplasia, 19(9), 716-733.